About Genenta Science S.p.A.
https://www.genenta.comGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
CEO
Pierluigi Paracchi
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
ALLIANZ SE
Shares:234.05K
Value:$330.01K
CARTESIAN GROWTH CORP
Shares:200.29K
Value:$282.41K
ALGEBRIS (UK) LTD
Shares:100K
Value:$141K
Summary
Showing Top 3 of 7
About Genenta Science S.p.A.
https://www.genenta.comGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $3.38M ▼ | $-3.83M ▲ | 0% | $-0.2 ▲ | $-3.37M ▲ |
| Q4-2024 | $0 | $5.25M ▲ | $-4.87M ▼ | 0% | $-0.27 ▼ | $-5.22M ▼ |
| Q2-2024 | $0 | $4.52M ▼ | $-4.04M ▲ | 0% | $-0.22 ▲ | $-4.5M ▲ |
| Q4-2023 | $0 | $4.93M ▼ | $-4.89M ▲ | 0% | $-0.27 ▲ | $-4.91M ▼ |
| Q2-2023 | $0 | $6.72M | $-6.7M | 0% | $-0.37 | $-3.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $17.67M ▲ | $21.55M ▲ | $9.44M ▲ | $12.11M ▼ |
| Q4-2024 | $12.66M ▼ | $14.82M ▼ | $2.33M ▲ | $12.5M ▼ |
| Q2-2024 | $16.91M ▼ | $19.02M ▼ | $2.2M ▲ | $16.82M ▼ |
| Q4-2023 | $18.78M ▼ | $22.35M ▼ | $1.91M ▼ | $20.43M ▼ |
| Q2-2023 | $22.21M | $26.73M | $1.92M | $24.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-3.83K ▲ | $-5.51K ▼ | $-4.44K ▼ | $10.48K ▼ | $5.18K ▼ | $-5.52K ▲ |
| Q4-2024 | $-8.91M ▼ | $-4.18K ▼ | $2.58K ▼ | $270.61K ▲ | $4.58M ▲ | $-6.24M ▼ |
| Q2-2024 | $-4.04K ▲ | $-2.06K ▲ | $4.3K ▲ | $270.88 ▲ | $6.19K ▲ | $-2.06K ▲ |
| Q4-2023 | $-4.89K ▲ | $-3.62K ▲ | $-4.89K ▲ | $0 | $-12.21K ▲ | $-3.63K ▲ |
| Q2-2023 | $-6.7M | $-7.51M | $-9.91M | $0 | $-17.42M | $-7.52M |
CEO
Pierluigi Paracchi
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
ALLIANZ SE
Shares:234.05K
Value:$330.01K
CARTESIAN GROWTH CORP
Shares:200.29K
Value:$282.41K
ALGEBRIS (UK) LTD
Shares:100K
Value:$141K
Summary
Showing Top 3 of 7